

# **SAES GETTERS**

Sector: Industrials

## **OUTPERFORM**

Price: Eu28.55 - Target: Eu39.00


### Some softness in 1Q23. Focus on saving shares conversion

### Enrico Coco +39-02-77115.230

enrico.coco@intermonte.it

Stock Rating			
Rating:			Unchanged
Target Price (Eu):			Unchanged
	2023E	2024E	2025E
Chg in Adj EPS	0.0%	0.0%	0.0%

#### SAES GETTERS - 12M Performance



SAES GETTERS — SAES GETTERS Rel. to FTSE All Shares (Reb.)

Stock Data			
Reuters code:		SAEI.MI	
Bloomberg code:			SG IM
Performance	1M	3M	12M
Absolute	-2.4%	-10.8%	25.2%
Relative	-1.3%	-10.8%	10.5%
12M (H/L)		33	.60/19.64
3M Average Volume (th):			18.51
Shareholder Data	a		
No. of Ord shares		15	
Total no. of share		15	
Mkt Cap Ord (Eu		419	
Total Mkt Cap (Eu		626	
Mkt Float - Ord (E		163	
Mkt Float (in %):		39.0%	
Main Shareholder:			
S.G.G. Holding 34.4%			34.4%
Balance Sheet Da	ita		
Book Value (Eu m		279	
BVPS (Eu):			12.66
P/BV:	P/BV:		2.3
Net Financial Pos	ition (Eu mr	n):	82
Enterprise Value (Eu mn):			544

1Q23 results in line, with some softness at industrial (ex Nitinol) businesses. SAES 1Q23 results showed some softness at industrial businesses ex Nitinol (in particular Chemicals, Packaging), partly anticipated by the weak sales trend of Jan-Feb already disclosed (+4.4% YoY and +0.7% ex ForEx). In 1Q23, sales were Eu60mn vs. Eu61mn expected, rising +1.7% YoY or -3.8% ex ForEx. Gross profit was Eu27mn with the margin up 30bps YoY to 44.3%. EBITDA was Eu11mn (18.1% margin) vs. Eu12mn expected and includes Eu2mn in one-offs related to the announced transaction with Resonetics at the Medical business; on a clean basis, the EBITDA margin was stable YoY at 23%. Net profit of Eu5mn (Eu4mn expected) vs. Eu2mn in 1Q22 includes Eu2mn of non-cash income from mark to market of financial investments. The net cash position was stable vs. FY22 at Eu64mn after a Eu7mn increase in working capital, mainly at the Medical business. The company provided the following proforma figures for SAES's 1Q23 perimeter ex Nitinol: sales Eu28mn (-10% YoY), EBITDA at breakeven, EBIT loss Eu3mn, net loss Eu2mn.

- Confidence on improving trends. In 1Q23, sales at SAES Medical were up 14% (+9% organic) to Eu32mn, while the industrial perimeter ex Nitinol (SAES Industrial, SAES High Vacuum, SAES Chemicals, SAES Packaging) reported a 10% YoY decline in sales to Eu28mn. This was driven by Chemicals (-44% YoY to Eu2mn) and Packaging (-56% YoY to Eu2mn), while SAES Industrial was up 4% to Eu19mn (strong industrial SMAs), and sales of SAES High Vacuum were stable at Eu7mn (consolidation of SAES Rial compensated lower sales vs. a particularly strong 1Q22). Management expressed confidence on improving operating trends in coming months. We note exposure to defensive businesses and growing industrial SMAs at SAES industrial, the positive outlook (and exposure to fusion energy) of High Vacuum (ca. Eu40mn sales in FY24e from ca. Eu30mn in FY22), the expected improvement at Chemicals, and the slow take-up at Packaging. We think SAES's industrial perimeter has significant growth potential.
- Estimates unchanged. Our estimates point to FY23 sales of Eu266mn (+6% YoY with SAES ex Nitinol growing ca. +4%), EBITDA of Eu64mn (before costs associated with the transaction with Resonetics) vs. Eu57mn in FY22, adj. net profit of Eu33mn.
- Focus on saving shares conversion. Management said it was working hard to complete the extraordinary transaction on saving shares (voluntary partial tender offer on 18.5% of savings at Eu29.31 per share and 1:1 mandatory conversion into ordinary shares), with an EGM and a special meeting of savings shareholders to be held on 31 May. We think the transaction is a valuation catalyst for the stock (rationalize the capital structure, standardize the right of all shareholders, increase the free-float, EPS accretive). No additional info on the transaction with Resonetics on the Nitinol business, expected to close by year-end.

Key Figures & Ratios	2020A	2021A	2022A	2023E	2024E
Sales (Eu mn)	169	190	250	266	289
EBITDA Adj (Eu mn)	27	36	57	64	71
Net Profit Adj (Eu mn)	5	13	29	33	38
EPS New Adj (Eu)	0.217	0.593	1.299	1.499	1.720
EPS Old Adj (Eu)	0.217	0.593	1.299	1.499	1.720
DPS (Eu)	0.400	0.470	0.550	0.550	0.550
EV/EBITDA Adj	13.6	10.8	6.6	8.6	4.5
EV/EBIT Adj	22.8	17.3	9.2	11.0	5.6
P/E Adj	nm	48.1	22.0	19.0	16.6
Div. Yield	1.4%	1.6%	1.9%	1.9%	1.9%
Net Debt/EBITDA Adj	-3.6	-2.1	-1.1	-1.3	-1.4

The reproduction of the information, recommendations and research produced by Intermonte SIM contained herein, and any of its parts, is strictly prohibited. None of the contents of this document may be shared with third parties without Company authorization. Please see important disclaimer on the last page of this report



#### DISCLAIMER (for more details go to DISCLAIMER)

IMPORTANT DISCLOSURES The reproduction of the information, recommendations and research produced by Intermonte SIM contained herein and of any its parts is strictly prohibited. None of the contents of this document may be shared with third parties without authorisation from Intermonte.

This report is directed exclusively at market professional and other institutional investors (Institutions) and is not for distribution to person other than "Institution" ("Non-Institution"), who should not rely on this material. Moreover, any The information and data in this report have been obtained from sources which we believe to be reliable, although the accuracy of these cannot be guaranteed by Intermonte. In the event that there be any doubt as to their reliability, this will be clearly indicated. The main purpose of the report is to offer up-to-date and accurate information in accordance with regulations in force covering "recommendations" and is not intended nor should it be construed as a the information and data in this report have been obtained from sources which we believe to be reliable, although the accuracy of these cannot be guaranteed by Intermonte. In the event that there be any doubt as to their reliability, this will be clearly indicated. The main purpose of the report is to offer up-to-date and accurate information in accordance with regulations in force covering "recommendations" and is not intended nor should it be construed as a

solicitation to buy or sell securities.

in disclamation to usy of sen accuracy.

question. For a list of all recommendations made by Intermonte on any financial instrument or issuer in the last twelve months consult the <u>PERFORMANCE</u> web page. Intermonte distributes research and engages in other approved activities with respect to Major U.S. Institutional Investors ("Majors") and other Qualified Institutional Buyers ("QIBs"), in the United States, via Brasil Plural Securities LLC under SEC 153-6 guidelines. Intermonte is not registered as a broker dealer in the United States under the Exchange Act of 1934, as amended (the "Exchange Act"), and is not a member of the Securities Investor Protection Corporation ("SIPC"). Brasil Plural Securities LLC is registered as a broker-dealer under the Exchange Act and is a member of SIPC.

#### ANALYST CERTIFICATION

tioned in this report the respective research analyst hereby certifies that all of the views expressed in this research report accurately reflect the analyst's personal views about any or all of the subject issuer (s) or For each company mentioned in this report the respective research analyst hereby certifies that all of the views expressed in this research report accurately reflect the analysts personal views about any or all of the subject issuer (s) or securities. The analyst (s) responsible for preparing this research report receive(s) compensation was, is or will be directly or indirectly related to the specific recommendation or view in this report. The analyst (s) responsible for preparing this research report receive(s) compensation that is based upon various factors, including intermonte's total profits, a portion of which is generated by Intermonte's corporate finance activities, although this is minimal in comparison to that generated by brokerage activities. Intermonte's internal procedures and codes of conduct are almed to ensure the impartiality of its financial analysts. The exchange of information between the Corporate Finance sector and the Research Department is prohibited, as is the exchange of information between the latter and the proprietary equity desk in order to prevent conflicts of interest when recommendations are made.

The analyst responsible for the report is not a) a resident of US; b) an associated person of a U.S. broker-dealer; c) supervised by a supervisory principal of a U.S. broker-dealer. This Research Report is distributed in the U.S. through Brasil Plural Securities LLC, 545 Madison Avenue, New York 10022.

#### GUIDE TO FUNDAMENTAL RESEARCH

The main methods used to evaluate financial instruments and set a target price for 12 months after the investment recommendation are as follows:
Discounted cash flow (DCF) model or similar methods such as a dividend discount model (DDM)

Comparison with market peers, using the most appropriate methods for the individual company analysed; among the main ratios used for industrial sectors are price/ earnings (P/E), EV/EBITDA, EV/EBIT, price/sales,

. Return on capital and multiples of adjusted net book value are the main methods used for banking sector stocks, while for insurance sector stocks return on allocated capital and multiples on net book value and embedded portfolio value are used For the utilities sector comparisons are made between expected returns and the return on the regulatory asset base (RAB) -

Some of the parameters used in evaluations, such as the risk-free rate and risk premium, are the same for all companies covered, and are updated to reflect market conditions. Currently a risk-free rate of 4.0% and a risk premium of 5.5% are being used.

#### Frequency of research: quarterly

Reports on all commanies listed on the S&PMIB40 Index, most of those on the MIDEX Index and the main small caps (regular coverage) are published at least once per quarter to comment on results and important newsflow. A draft copy of each report may be sent to the subject company for its information (without target price and/or recommendations), but unless expressly stated in the text of the report, no changes are made before it is published Explanation of our ratings system:

BUY: stock expected to outperform the market by over 25% over a 12 month period;

OUTPERFORM: stock expected to outperform the market by between 10% and 25% over a 12 month period;

NUTRAL: stock performance expected a between +10% and -10% compared to the market over a 12 month period; UNDERPERFORM: stock expected to underperform the market by between -10% and -25% over a 12 month period; SEL: stock expected to underperform the market by over 25% over a 12 month period. Prices: The prices reported in the research refer to the price at the close of the previous day of trading

#### CURRENT INVESTMENT RESEARCH RATING DISTRIBUTIONS

Intermonte SIM is authorised by CONSOB to provide investment services and is listed at n° 246 in the register of brokerage firms As at 31 March 2023 Intermonte's Research Department covered 119 companies. Intermonte's distribution of stock ratings is as as follows

BUY:	20.83 %
OUTPERFORM:	51.67 %
NEUTRAL:	25.83 %
UNDERPERFORM	01.67 %
SELL:	00.00 %

The distribution of stock ratings for companies which have received corporate finance services from Intermonte in the last 12 months (49 in total) is as follows:

BUY:	38.78 %
OUTPERFORM:	51.02 %
NEUTRAL:	10.20 %
UNDERPERFORM	00.00 %
SELL:	00.00 %

#### CONFLICT OF INTEREST

#### In order to disclose its possible conflicts of interest Intermonte SIM states that:

Intermonte SIM is acting as Global Coordinator in the proposed Unidata's capital increase with an agreement with the company for the publication of an equity research regarding the company and the transaction

Intermonte SIM is acting as Global Coordinator in the proposed Unidata's capital increase with an agreement with the company for the publication of an equity research regarding the company and the transaction Intermonte is acting as financial advisor to SACS Getters in relation to the partial voluntary tender offer on saving shares and mandatory conversion of saving shares into ordinary shares proposed by the company. Intermonte is also acting as Listing Agent in the proposed Unidata's Translisting. Intermonte will receive fees from the company for its activity as Global Coordinator and Listing Agent. Within the last year, Intermonte SIM managed or co-managed/is managing or is co-managing an Institutional Offering and/or managed or co-managed/is managing or is co-managing an offering with firm committee of the following Companies: Civitanavi Systems, GPI. Intermonte SIM has provided in the last 12 months / provide investment banking services to the following companies: Aedes, Cy4Gate, Esprinet, GPI, Greenthesis (formerly Ambienthesis), Growens, Maire Tecnir aging an offering with firm commitment underwriting of the securities

ovides / may provide investment banking services to the following companies: Aedes, Cy4Gate, Esprinet, GPI, Greenthesis (formerly Ambienthesis), Growens, Maire Tecnimont, Tinexta, Unidata and WIIT.

Intermote SIM is Specialist and/or Corporate Broker and/or Sponsor and/or Broker in charge of the share buy back activity of the following companies: Abitare In, Addes, Alkemy, Anime Technikov, Anime Technikov, Mile Techni

Intermonte sin has a contractual commitment to act as inquisity provider on benair or mino parties for the roliowing companies. Act have the objective contractual commitment to act as inquisity provider on benair or mino parties for the roliowing companies. Act have the objective contractual commitment to act as inquisity provider on benair or mino parties for the roliowing companies. Act have the objective contractual commitment of the following companies. Act have the objective contractual commitment of the following companies. Act have the digital factor and the digital division of intermonte, single for the following companies. Act have the digital division of intermonte single for the following companies. Act have the digital division of intermonte for the following companies. Act have the digital division of intermonte act as a Financial Content Provider on the following companies. Activate in, Alkemy, Banca Steema, Bifire S.P.A., B&C Speakers, Cleanohob, Comer industries, Crowdfundme, Cydgate, Cyberoo, Digital Roso, Roso et alternation and the context of Group, Relatech, Reti, Salcef Group, Sciuker Frames, Sebino, Solid World Group, Spindox Digital Soul, Supplymecapital, Tamburi, Tesmec, The Italian Sea Group, Tinexta, Tps Group, Trendevice, Triboo, Ulisse Biomed, Vantea Smart, Wiit. Intermonte SIM SpA holds net long or short positions in excess of 0.5% of the overall share capital in the following issuers:

#### Emittente % Long/Short

#### © Convright 2023 by Intermonte SIM - All rights reserved

It is a violation of national and international copyright laws to reproduce all or part of this publication by email, xerography, facsimile or any other means. The Copyright laws impose heavy liability for such infringement. The Reports of Intermonte SIM are provided to its clients only. If you are not a client of Intermonte SIM and receive emailed, faxed or copied versions of the reports from a source other than Intermonte SIM you are violating the Copyright Laws. This document is not for attribution in any publication, and you should not disseminate, distribute or copy this e-mail without the explicit written consent of Intermonte SIM.

INTERMONTE will take legal action against anybody transmitting/publishing its Research products without its express authorization. INTERMONTE Sim strongly believes its research product on Italian equities is a value added product and deserves to be adequately paid. Intermonte Sim sales representatives can be contacted to discuss terms and conditions to be supplied the INTERMONTE research produc

INTERMONTE SIM is MIFID compliant - for our Best Execution Policy please check our Website MIFID Further information is available